Abby Hardy, Author at BioTuesdays

Developments

Concert completes enrollment in Phase 2 schizophrenia trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia. The trial enrolled 325 patients already on a stable course...

September 29, 2020

Developments

Field Trip Psychedelics completes GLP synthesis of FT-104

Closely-held Field Trip Psychedelics successfully completed GLP synthesis of its psychedelic molecule, FT-104. FT-104 is a new chemical substance designed to be a commercially viable alternative to naturally derived...

September 29, 2020

Executive Moves

PharmaJet appoints Melissa Malhame as VP business development

Melissa Malhame Closely-held PharmaJet appointed Melissa Malhame as its VP of business development, where she will lead the company’s business development, sales, and marketing operations. “[Ms. Malhame’s] strategic...

September 29, 2020

Developments

Imagin Medical to host KOL webcast on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will host a virtual investor event with key opinion leaders on Oct. 29 at 12:00 pm ET to highlight the potential of the company’s i/Blue...

September 29, 2020

Developments

Soricimed receives $500,000 in Government of Canada funding

Closely-held Soricimed Biopharma received $500,000 in funding from the Government of Canada to support the company’s continued research and development work. The Government of Canada provided the repayable contribution...

September 29, 2020

Developments

Zucara doses first subject in Phase 1 trial of ZT-01

Closely-held Zucara Therapeutics dosed the first subject in its Phase 1 trial of ZT-01, a once-daily somatostatin inhibitor designed to prevent insulin-induced hypoglycemia. The first, single ascending dose portion...

September 29, 2020

Developments

Kane Biotech, Animalcare to form STEM Animal Health

Kane Biotech (TSX-V:KNE) and UK-based Animalcare Group (AIM:ANCR) signed a pact to form STEM Animal Care, a company dedicated to treating biofilm-related ailments in animals. Under the accord, Animalcare will launch...

September 28, 2020

Developments

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 fast track designation for gastric and gastroesophageal junction cancer. Specifically, the designation was granted for patients whose tumors express high Dickkopf...

September 24, 2020

Developments

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

The FDA granted Mereo BioPharma’s (NASDAQ:MREO) setrusumab rare pediatric disease designation for the treatment of osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is caused by a genetic mutation in...

September 24, 2020

Developments

Applied Therapeutics AT-007 gets FDA rare pediatric disease and orphan drug designations

The FDA granted Applied Therapeutics’ (NASDAQ:APLT) AT-007 rare pediatric disease and orphan drug designations for the treatment of PMM2-congenital disorder of glycosylation (PMM2-CDG). PMM2-CDG is a rare disease caused...

September 24, 2020

Author - Abby Hardy

Concert completes enrollment in Phase 2 schizophrenia trial

Field Trip Psychedelics completes GLP synthesis of FT-104

PharmaJet appoints Melissa Malhame as VP business development

Imagin Medical to host KOL webcast on Oct. 29

Soricimed receives $500,000 in Government of Canada funding

Zucara doses first subject in Phase 1 trial of ZT-01

Kane Biotech, Animalcare to form STEM Animal Health

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

Applied Therapeutics AT-007 gets FDA rare pediatric disease and orphan drug designations

General

More